Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

Antiviral Therapy

Volumn 14, Issue 2, 2009, Pages 195-201

  Pulido, Federico ^a   Pérez Valero, Ignacio ^b   Delgado, Rafael ^a   Arranz, Alberto ^c   Pasquau, Juan ^d   Portilla, Joaquin ^e   Rubio, Rafael ^a   González García, Juan ^b   Miralles, Pilar ^f   Pérez Elias, Maria J ^g   Ocampo, Antonio ^h   Hernando, Asunción ^a,i   Estrada, Vicente ^j   Clotet, Bonaventura ^k   Podzamczer, Daniel ^l   Arribas, José R ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

ⁱ UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; VIRUS RNA; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; VIRUS INHIBITION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PYRIMIDINONES; RISK FACTORS; RITONAVIR; RNA, VIRAL;

EID: 67149121193     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November 2008. (Updated 3 November 2008. Accessed 18 February 2009.) Available from www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
2. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007; 370:12-14.
3. Escobar I, Pulido F, Perez E, Arribas JR, Garcia MP, Hernando A. Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ ritonavir monotherapy in HIV infected patients. Enferm Infecc Microbiol Clin 2006; 24:490-494.
4. Cameron DW, Da Silva B, Arribas JR, et al. A 96-week comparison of lopinavir/ritonavir combination therapy followed by lopinavir/ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240.
5. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplication: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45:1062-1070.
6. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
7. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287.
8. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
9. Sprinz E, Bay MB, Lazzaretti RK, Jeffman MW, Mattevi VS. Lopinavir/ ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. HIV Med 2008; 9:270-276.
10. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16:605-613.
11. Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ ritonavir once daily and lopinavir/ritonavir twice daily and once daily over 72 h following drug cessation. Antivir Ther 2008; 13:901-907.
12. Campo R, Cotte L, Gathe J, et al. Predictors of loss of virologic response in subjects who deintensified to lopinavir/ritonavir monotherapy after achieving plasma HIV-1 RNA <50 copies/ml on lopinavir/ ritonavir plus zidovudine/lamivudine. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 514.
13. Wainberg MA, Clotet B. Immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review. AIDS Patient Care STDS 2007; 21:609-620.
14. Riddler SHR, Haubrich R, DiRienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
15. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
16. + Kenyan adults. J Nutr 2008; 138:613-619.
17. Weiss G, Schroecksnadel K, Mattle V, Winkler C, Konwalinka G, Fuchs D. Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation. Eur J Haematol 2004; 72:130-134.
18. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:54-57.